Topic summary
Irish differences from the UK position — what changed since
This is a generated summary. It shows the 5 most-liked posts from a topic of 13, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
On the opening post — agreed on the reasoning, with one qualification.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
16 likes 10d
p.mbeki, post #5: Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI. Go to post
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
trough_index, post #3: On the opening post — agreed on the reasoning, with one qualification. MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs. Go to post
NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.
Read the full topic (13 posts)
This topic was referenced in
- Pharmacy supply in the UK and the questions you will be askedRegional › UK & Ireland · 105 replies
- MHRA statements, read directly — the long versionRegional › UK & Ireland · 2 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category expires.…
|
+62 | 66 | 993 | 21mo |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A coverage question with the paperwork detail…
|
+11 | 15 | 11k | 9mo |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that…
|
+62 | 67 | 2.1k | 6mo |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 5.8k | 15mo | |
|
Private prescribing in the UK: what is actually involved
On the subject in the title: Private prescribing in the UK: what is actually involved Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+66 | 76 | 46k | 14h |
Related topics — sharing the tags personal import, cost per milligram, NHS
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+23 | 28 | 45k | 21mo |
|
Second pass at: Manufacturer assistance programmes and their eligibility rules
Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in…
|
+13 | 17 | 1.8k | 16mo |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…
|
+100 | 110 | 37k | 5mo |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
|
+76 | 82 | 52k | 11mo |
|
About the Pricing category
List prices, negotiated prices, and cost per milligram compared honestly across formats. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+1 | 5 | 18k | 15mo |